Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Requirement for safety monitoring for approved MS therapies - An overview.
New diagnostic criteria for multiple sclerosis in patients with clinically isolated syndromes: Some questions could be raised during clinical practice.
Frequency distribution of the first clinical symptoms in the Iranian population with multiple sclerosis.
Optic neuritis due to immunobiologics: first Brazilian case report.
Determination of Brain Volumes Using Quantitative MR Imaging in Patients with Multiple Sclerosis.
CNS accumulation of regulatory B cells is VLA-4-dependent.
Comments on "first-ever optic neuritis: distinguishing subsequent neuromyelitis optica from multiple sclerosis"
Acquired CNS Demyelinating Syndrome in Children Referred to ShirazPediatric Neurology Ward.
Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis.
[Treatment for multiple sclerosis in patients with collagen diseases].
Unveiling the anti-inflammatory activity of Sutherlandia frutescens using murine macrophages.
Disease-related and functional predictors of employment status among adults with multiple sclerosis.
Therapeutic Intervention in Multiple Sclerosis with Alpha B-Crystallin: A Randomized Controlled Phase IIa Trial.
Onset-adjusted incidence of multiple sclerosis in the Girona province (Spain): Evidence of increasing risk in the south of Europe.
25-hydroxyvitamin D levels are associated with multiple sclerosis in Iran: A cross-sectional study.
Olfactory Dysfunction in Multiple Sclerosis: Evidence of a Decrease in Different Aspects of Olfactory Function.
Can "dissemination" include the PNS in adults with acute disseminated encephalomyelitis?
Oral therapy approved for multiple sclerosis.
Neuronal Hemoglobin Expression and Its Relevance to Multiple Sclerosis Neuropathology.
Whole-brain atrophy: ready for implementation into clinical decision-making in multiple sclerosis?
A critical role for interleukin-1β in the progression of autoimmune diseases.
Helminth/Parasite treatment of multiple sclerosis.
The gender-specific association of CXCL16 A181V gene polymorphism with susceptibility to multiple sclerosis, and its effects on PBMC mRNA and plasma soluble CXCL16 levels: preliminary findings.
Cell surface levels of endothelial ICAM-1 influence thetranscellular or paracellularT-celldiapedesis across the blood-brain barrier.
Quantification of sulfatides and lysosulfatides in tissues and body fluids by liquid chromatography tandem mass spectrometry.
Pages
« first
‹ previous
…
596
597
598
599
600
601
602
603
604
…
next ›
last »